Owns Newsight Tech Angels LLC as a U.S. subsidiary
Within the Angel Investment Fund, investment recovery will be made through the following.
- Approx. 60%: Investments in Japanese drug discovery seeds and platform technologies
- Approx. 20%: Investments in non-Japanese drug discovery seeds and platform technologies
- 20%: Portfolio investment in U.S. angel funds
- As a result of hands-on support:
- Licensing to Asian countries including Japan
- Partnerships with pharmaceutical companies
- Venture capital funding